The Pharmacy Times® Zoster resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
The FDA has approved mepolizumab for the treatment of hypereosinophilic syndrome.
The FDA has approved tofacitinib for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis.
Though more research is needed, reactivation of the varicella-zoster virus may be caused by a decrease in absolute lymphocytes caused by COVID-19.
In a comprehensive systematic review that assessed risk factors for HZ infection, researchers found that immunosuppression through HIV/AIDS or malignancy places individuals at a significant risk.
Despite some challenges, these programs increase rates and follow-up doses and improve patient communication.
Room for improvement remains, based on 3 factors identified by WHO: complacency, confidence, and convenience.
Improving Vaccination Rates for Unvaccinated and Undervaccinated Groups and Other Vulnerable Populations
Pharmacists have become widely accepted as immunization advocates, educators, and administrators, and an increasing proportion of influenza vaccines are being administered in community pharmacies nationwide.
Counseling pearls and considerations for the shingles vaccine, such as navigating insurance coverage, managing adverse events, and handling a missed dose in the series, are discussed.
Study findings could lead to new treatments and vaccines for other herpesviruses, as well as HIV, coronaviruses, and other conditions, all of which rely on the same protein.
At the Advisory Committee on Immunization Practices' June 2020 meeting, the agenda included discussions of the meningococcal vaccine, influenza vaccine, and coronavirus disease 2019 (COVID- 19).
The COVID-19 pandemic serves as an important reminder of basic recommendations for ensuring health and wellness and protecting oneself against communicable disease transmission.
Researchers used 2 pairs of genetic scissors to remove latent herpes simplex virus 1, an approach they say should move toward clinical trials.